|Day's range||50.49 - 50.93|
|52-week range||37.38 - 51.13|
|PE ratio (TTM)||52.90|
|Earnings date||17 Oct 2017 - 23 Oct 2017|
|Dividend & yield||1.06 (2.08%)|
|1y target est||52.63|
To improve clinical outcomes and increase the number of patients treated in the United States using Impella, Abiomed has launched the Abiomed Impella Quality Program.
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16.
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.